Anzeige
Mehr »
Login
Samstag, 20.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Breaking News: Voller Fokus auf NurExone Biologic!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
163 Leser
Artikel bewerten:
(0)

ADM Tronics Unlimited Inc.: ADM Tronics Reports Financial Results for Second Quarter of Fiscal Year 2019

NORTHVALE, NJ / ACCESSWIRE / November 19, 2018 / ADM Tronics Unlimited, Inc. (OTCQB: ADMT), a technology-based developer and manufacturer of innovative technologies and products, today announced results for its second fiscal quarter ended September 30, 2018 of Fiscal Year 2019.

As previously announced, ADMT has been redirecting more of its engineering resources towards advancement of its suite of proprietary medical technologies. This includes Alvio®, respiratory training and therapeutic device for asthma, COPD and other respiratory sufferers, which is in final stages of development; Aurex-3®, non-invasive therapeutic technology for the treatment and control of tinnitus; and, Sonotron®, non-invasive treatment modality for pain. As ADMT advances these technologies through stages of development, revenues were reduced from customers of engineering services and medical device manufacturing, while posting a profit for the quarter.

Revenues for the six months ended September 30, 2018 were $1,611,663 as compared to $2,077,494 for the six months ended September 30, 2017, a decrease of 22%. Income from operations for the second quarter was $103,551 as compared to $80,576 for the same period last year, an increase of 29%.

Revenues for the three months ended September 30, 2018 were $854,696 as compared to $931,139 for the three months ended September 30, 2017, a decrease of 8%. Income from operations for the second quarter was $86,455 as compared to $76,835 for the same period last year, an increase of 13%.

Complete financial results are available in the Company's Quarterly Report on Form 10Q available at sec.gov.


Financial Highlights

Three Months Ended Six Months Ended
September 30, September 30,
2018 2017 2018 2017
Net Revenues
$ 854,696 $ 931,139 $ 1,611,663 $ 2,077,494
Cost of Sales
$ 332,617 $ 351,894 $ 637,038 $ 972,689
Gross Profit
$ 522,079 $ 579,245 $ 974,625 $ 1,104,805
Operating Expenses
$ 435,624 $ 502,410 $ 871,074 $ 1,024,229
Income from operations
$ 86,455 $ 76,835 $ 103,551 $ 80,576
Total other income
$ 5,952 $ 4,201 $ 11,473 $ 5,093
Income before provision for (benefit from) income taxes
$ 92,407 $ 81,036 $ 115,024 $ 85,669
Total provision for (benefit from) income taxes
$ (26,000) $ 81,000 $ (26,000) $ 158,000
Net income (loss)
$ 118,407 $ 36 $ 141,024 $ (72,331)
Basic and diluted earnings per common share
$ 0.00 $ 0.00 $ 0.00 $ 0.0
Weighted average shares of common stock outstanding - diluted
67,588,492 67,588,492 67,588,492 67,588,492

About ADMT

ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Eco-Friendly, Safe, Water-Based Formulations; and, Design, Engineering, Regulatory and Manufacturing Services. The Company's headquarters, laboratories, FDA-Registered medical device and manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, such as 3-D solid prototyping, precision instrumentation and specialized software and peripherals, for the research, development and commercialization of diversified technologies. Additional information is available at the Company's websites - admtronics.com and concepttoquantity.com.

Except for historical information contained herein, the matters set forth in this news release are "forward looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.

Contact: Andre' DiMino 201-767-6040, andre@admtronics.com

SOURCE: ADM Tronics Unlimited, Inc.



View source version on accesswire.com:
https://www.accesswire.com/528486/ADM-Tronics-Reports-Financial-Results-for-Second-Quarter-of-Fiscal-Year-2019

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2018 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.